Amanda Landers1, Wendy Muircroft2, Helen Brown1. 1. Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand. 2. Department of Palliative Care, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Abstract
PURPOSE: The diagnosis of metastatic pancreatic cancer (PC) carries a poor prognosis. PC is associated with weight loss and malabsorption in high rates secondary to pancreatic exocrine insufficiency. UK and USA guidelines exist recommending the empiric use of pancreatic enzyme replacement therapy (PERT) for quality of life in these patients. The aim of this study is to review the use of PERT in patients with metastatic PC referred to a specialist palliative care service. METHODS: Retrospective observational study of patients referred to the service between January 2010 and July 2012 with a diagnosis of PC. Information about PERT use, tumour site and frequency of symptoms was collected. RESULTS: 129 patients were referred, with a higher number in the eighth decade. Only 21% of this study group were prescribed PERT. Over 70% of patients had symptoms that could be attributable to malabsorption, mainly abdominal pain. Other symptoms such as bloating, wind and steatorrhoea were also common. CONCLUSIONS: Guidelines recommending empiric treatment of PERT in patients with metastatic PC are not currently being utilised. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
PURPOSE: The diagnosis of metastatic pancreatic cancer (PC) carries a poor prognosis. PC is associated with weight loss and malabsorption in high rates secondary to pancreatic exocrine insufficiency. UK and USA guidelines exist recommending the empiric use of pancreatic enzyme replacement therapy (PERT) for quality of life in these patients. The aim of this study is to review the use of PERT in patients with metastatic PC referred to a specialist palliative care service. METHODS: Retrospective observational study of patients referred to the service between January 2010 and July 2012 with a diagnosis of PC. Information about PERT use, tumour site and frequency of symptoms was collected. RESULTS: 129 patients were referred, with a higher number in the eighth decade. Only 21% of this study group were prescribed PERT. Over 70% of patients had symptoms that could be attributable to malabsorption, mainly abdominal pain. Other symptoms such as bloating, wind and steatorrhoea were also common. CONCLUSIONS: Guidelines recommending empiric treatment of PERT in patients with metastatic PC are not currently being utilised. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Daniel de la Iglesia; Bartu Avci; Mariia Kiriukova; Nikola Panic; Maryana Bozhychko; Vasile Sandru; Enrique de-Madaria; Gabriele Capurso Journal: United European Gastroenterol J Date: 2020-07-06 Impact factor: 4.623
Authors: William Paul Skelton; Hiral Parekh; Jason S Starr; Jose Trevino; Jessica Cioffi; Steven Hughes; Thomas J George Journal: J Gastrointest Cancer Date: 2018-03
Authors: Benjamin M Shandro; Jennifer Ritehnia; Joshua Chen; Rani Nagarajah; Andrew Poullis Journal: Clin Med (Lond) Date: 2020-11 Impact factor: 2.659
Authors: Miroslav Vujasinovic; Roberto Valente; Marco Del Chiaro; Johan Permert; J-Matthias Löhr Journal: Nutrients Date: 2017-02-23 Impact factor: 5.717
Authors: Agnieszka Lemanska; Colm Andrews; Louis Fisher; Ben Butler-Cole; Amir Mehrkar; Keith J Roberts; Ben Goldacre; Alex J Walker; Brian MacKenna Journal: medRxiv Date: 2022-08-31
Authors: Juan Enrique Domínguez-Muñoz; Laura Nieto-Garcia; Javier López-Díaz; Jose Lariño-Noia; Ihab Abdulkader; Julio Iglesias-Garcia Journal: BMC Cancer Date: 2018-05-05 Impact factor: 4.430